Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia.
Imatinib is presently the commonest prescribes drug for patients of chronic myelogenous leukemia (CML) in chronic phase (CP) worldwide. Its ocular side effects are little known. Optic neuritis caused by this drug has not been reported (Medline search). We describe perhaps the first case of optic neuritis caused by this drug.
Govind Babu
K
K
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore, 560 029, India.
Attili
Venkata Satya Suresh
VS
Bapsy
P P
PP
Anupama
G
G
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001549:Benzamides; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009902:Optic Neuritis / Q000139:chemically induced* / Q000188:drug therapy; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome; D014786:Vision Disorders / Q000139:chemically induced / Q000188:drug therapy
D000970:Antineoplastic Agents; D001549:Benzamides; D005938:Glucocorticoids; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011239:Prednisolone